|
BCL7B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.36669999994954E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.7993199999955E-05 |
| Normal-vs-Stage2 |
7.963500E-02 |
| Normal-vs-Stage3 |
4.87510000035662E-07 |
| Normal-vs-Stage4 |
4.79900000005529E-06 |
| Stage1-vs-Stage2 |
6.606300E-02 |
| Stage1-vs-Stage3 |
1.320000E-01 |
| Stage1-vs-Stage4 |
7.474100E-02 |
| Stage2-vs-Stage3 |
7.619100E-03 |
| Stage2-vs-Stage4 |
8.498300E-03 |
| Stage3-vs-Stage4 |
5.389600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.25169999998231E-06 |
| Normal-vs-AfricanAmerican |
2.082400E-02 |
| Normal-vs-Asian |
8.200700E-03 |
| Caucasian-vs-AfricanAmerican |
4.713200E-01 |
| Caucasian-vs-Asian |
2.214200E-01 |
| AfricanAmerican-vs-Asian |
8.635000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.82430000053679E-07 |
| Normal-vs-Female |
2.22809999999019E-05 |
| Male-vs-Female |
1.514810E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.04290000000085E-05 |
| Normal-vs-Age(41-60Yrs) |
1.73064999999806E-05 |
| Normal-vs-Age(61-80Yrs) |
1.53771999999996E-05 |
| Normal-vs-Age(81-100Yrs) |
4.652200E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.771200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.515400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.628800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.589400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.189200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.546760E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.5974299999999E-05 |
| Classical-VS-Follicular |
6.626400E-02 |
| Classical-VS-Other |
6.876600E-01 |
| Classical-VS-Normal |
2.35360000000462E-06 |
| Tall-VS-Follicular |
1.06879999994813E-06 |
| Tall-VS-Other |
3.282800E-01 |
| Tall-VS-Normal |
1.09099951295377E-10 |
| Follicular-VS-Other |
3.872400E-01 |
| Follicular-VS-Normal |
1.705850E-02 |
| Other-VS-Normal |
3.992300E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.41269999999849E-05 |
| Normal-vs-N1 |
2.00930000004984E-06 |
| N0-vs-N1 |
2.610200E-02 |
|
|
